These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6937954)

  • 21. Aspects on antibacterial treatment of anaerobic infections.
    Nordbring F; Nord CE
    Scand J Infect Dis Suppl; 1982; 35():59-62. PubMed ID: 6762654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice.
    Goering RV; Sanders CC; Sanders W
    J Antibiot (Tokyo); 1978 Apr; 31(4):363-72. PubMed ID: 306989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diffusion of cefotaxime in the interstitial fluid of rabbits. Comparison with cefazolin, cefoxitin and cefamandole (author's transl)].
    Boussougant Y; Contrepois A; Doquir C; Carbon C
    Nouv Presse Med; 1981 Feb; 10(8):591-3. PubMed ID: 6259599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity and synergism of cefuroxime on anaerobic bacteria.
    Thadepalli H; White DW; Bach VT
    Chemotherapy; 1981; 27(4):252-8. PubMed ID: 7249787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefamandole and cefoxitin.
    Sanders CV; Greenberg RN; Marier RL
    Ann Intern Med; 1985 Jul; 103(1):70-8. PubMed ID: 3890658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of cefoxitin and parenterally administered cephalosporins against anaerobic bacteria.
    Sutter VL; Kirby B; Finegold SM
    Rev Infect Dis; 1979; 1(1):218-23. PubMed ID: 318226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefamandole and cefoxitin.
    Med Lett Drugs Ther; 1979 Feb; 21(3):13-5. PubMed ID: 310945
    [No Abstract]   [Full Text] [Related]  

  • 29. In vivo inoculum effect and resistance selection with cefamandole and cefoxitin against Enterobacter cloacae in mice.
    Miller AK; Celozzi E; Pelak BA; Birnbaum J; Stapley EO
    J Antimicrob Chemother; 1980 Nov; 6(6):804-6. PubMed ID: 7002900
    [No Abstract]   [Full Text] [Related]  

  • 30. Cefamandole for treatment of obstetrical and gynecological infections.
    Cunningham FG; Gilstrap LC; Kappus SS
    Scand J Infect Dis Suppl; 1980; suppl 25():75-82. PubMed ID: 7010540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-generation cephalosporins.
    Glatt AE
    Hosp Pract (Off Ed); 1986 Mar; 21(3):158A-158B, 158E, 158H-158L. PubMed ID: 3081544
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of obstetric and gynecologic infections with cefamandole.
    Cunningham FG; Gilstrap LC; Kappus SS
    Am J Obstet Gynecol; 1979 Mar; 133(6):602-10. PubMed ID: 426015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of intravenous cefoxitin sodium in patients with obstetric/gynaecologic infections.
    White JS; Gee C; Ledger WJ
    J Antimicrob Chemother; 1978 Jul; 4(B):239-40. PubMed ID: 357395
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of antibiotics on the prevention of experimental Bacteroides fragilis endocarditis.
    Goldman PL; Durack DT; Petersdorf RG
    Antimicrob Agents Chemother; 1978 Nov; 14(5):755-60. PubMed ID: 727764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the in-vivo efficacy of Sch 34343.
    Loebenberg D; Moss EL; Rudeen J; Menzel F; Hare RS; Oden EM; Lin CC; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():207-18. PubMed ID: 3897173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of serious anaerobic infections.
    Greenberg RN; Scalcini MC; Sanders CV; Lewis AC
    Scand J Infect Dis Suppl; 1980; suppl 25():84-8. PubMed ID: 7010541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotics fail to prevent abscess formation secondary to bacteria trapped in fibrin clots.
    Hau T; Jacobs DE; Hawkins NL
    Arch Surg; 1986 Feb; 121(2):163-8. PubMed ID: 3511886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing antibiotic dose decreases polymicrobial infection after hemorrhagic shock.
    Livingston DH; Malangoni MA
    Surg Gynecol Obstet; 1993 May; 176(5):418-22. PubMed ID: 8480263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost containment of the second-generation cephalosporins by prospective monitoring at a community teaching hospital.
    Williams RR; Gross PA; Levine JF
    Arch Intern Med; 1985 Nov; 145(11):1978-81. PubMed ID: 4062447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.